natgillin/translations-raw huggingface dataset:
Efient contains lactose.
Efient sadrži laktozu
Efient is contraindicated in patients with severe hepatic impairment (Child Pugh class C).
Efient je kontraindiciran u bolesnika s teškim oštećenjem jetre (Child-Pugh stadij C).
Efient should be initiated with a single 60 mg loading dose and then continued at 10 mg once a day.
Liječenje lijekom Efient treba započeti jednokratnom udarnom dozom od 60 mg, a zatim nastaviti s 10 mg jedanput na dan.
Efient should not be used in children and adolescents below 18 years of age.
Efient se ne smije koristiti u djece i adolescenata mlađih od 18 godina.
Efient, which contains the active substance prasugrel, belongs to a group of medicines called anti- platelet agents.
Efient, koji sadrži djelatnu tvar prasugrel, pripada skupini lijekova koji se nazivaju antitrombocitni lijekovi.
Eflornithine slows down the growth of hair through its effect on a specific enzyme (a protein in the body involved in the production of hair).
Eflornitin usporava rast dlaka djelovanjem na specifičan enzim (protein u tijelu uključen u nastanak dlaka).
efmoroctocog alfa (recombinant coagulation factor VIII)
efmoroktokog alfa (efmoroctocog alfa) (rekombinantni faktor zgrušavanja krvi VIII)
Efmoroctocog alfa (recombinant human coagulation factor VIII, Fc fusion protein (rFVIIIFc)) has 1890 amino acids.
Efmoroktokog alfa (rekombinantni ljudski koagulacijski faktor VIII, Fc fuzijski protein (rFVIIIFc)) ima 1890 aminokiselina.
efmoroctocog alfa recombinant coagulation factor VIII IV
efmoroctocog alfa rekombinantni faktor zgrušavanja krvi VIII i.v.
efmoroctocog alfa recombinant coagulation factor VIII, Fc fusion protein
efmoroctocog alfa rekombinantni faktor zgrušavanja krvi VIII, Fc fuzijski protein
EFS (median)
EFS (medijan)
eftrenonacog alfa recombinant coagulation factor IX IV
eftrenonacog alfa rekombinantni faktor zgrušavanja krvi IX i.v.
eftrenonacog alfa recombinant coagulation factor IX, Fc fusion protein
eftrenonakog alfa (eftrenonacog alfa) (fuzijski protein rekombinantnog faktora zgrušavanja krvi IX i Fc fragmenta)
EFV + IDV + NRTIs
EFV + IDV + NRTI
EFV + NFV + NRTIs
EFV + NFV + NRTI
EFV + NRTIs
EFV + NRTI
EFV = efavirenz; FTC = emtricitabine; TDF = tenofovir disoproxil fumarate; E/C/F/TDF = elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate a Week 48 window was between Day 294 and 377 (inclusive).
EFV = efavirenz; FTC = emtricitabin; TDF = tenofovirdizoproksilfumarat; E/C/F/TDF = elvitegravir/kobicistat/emtricitabin/tenofovirdizoproksilfumarat a Okvir 48. tjedna bio je između 294. i 377. dana (uključujući).
EFV = efavirenz; RPV = rilpivirine
EFV = efavirenz; RPV = rilpivirin
EFV/TDF/FTC
N=411
EFV/TDF/FTC = efavirenz 600 mg, tenofovir 300 mg, emtricitabine 200 mg in the form of Atripla FDC.
EFV/TDF/FTC = efavirenz 600 mg, tenofovir 300 mg, emtricitabin 200 mg u obliku kombinacije fiksnih doza Atripla.
EGFR
Negativni na
EGFR
p=0,0012
EGFR
Pozitivni na
EGFR activates proteins called RAS.
EGFR aktivira bjelančevine nazvane RAS.
eGFR improvement
eGFR poboljšanje
eGFR improvement ≥ 15 mL/min/1.73m2
Poboljšanje eGFR ≥15 ml/min/1,73m2
eGFR improvement ≥15 mL/min/ 1.73•m2, n (%)
Poboljšanje eGFR ≥15 ml/min/1,73•m2, n (%)
EGFR is a transmembrane glycoprotein that is a member of a subfamily of type I receptor tyrosine kinases including EGFR (HER1/c-ErbB-1), HER2, HER3, and HER4.
EGFR je transmembranski glikoprotein koji pripada podskupini receptora tirozin-kinaza tipa I u koju se ubrajaju EGFR (HER1/c-ErbB-1), HER2, HER3 i HER 4.
EGFR mutation status and clinical characteristics
Status mutacije EGFR-a i klinička obilježja
EGFR mutation testing should be performed prior to initiation of Tarceva therapy in chemo-naïve patients with advanced or metastatic NSCLC.
Prije uvođenja liječenja lijekom Tarceva u bolesnika s uznapredovalim ili metastatskim NSCLC-om koji prethodno nisu primali kemoterapiju, treba napraviti testiranje na mutaciju EGFR.
EGFR mutation-
mutacija EGFR
EGFR promotes cell growth in normal epithelial tissues, including the skin and hair follicle, and is expressed on a variety of tumour cells.
EGFR stimulira rast stanica u normalnim epitelnim tkivima, uključujući kožu i folikul dlake te je eksprimiran na stanicama različitih vrsta tumora.
EGFR T790M mutation status should be determined by using a validated test method (see section 4.4).
Status T790M mutacije EGFR-a treba se odrediti korištenjem validirane metode testiranja (vidjeti dio 4.4).
eGFR ≥60 to <90 ml/min/1.73 m²
eGFR ≥60 do <90 ml/min./1,73 m²
Eggs (chicken): zero days.
Jaja (pilići): nula dana
Eggs (chicken): zero days.
Jaja (pilići): nula dana.
Eggs: zero days
Jaja: nula dana
Eggs: zero days
Jaja: nula dana.
Egis Pharmaceuticals PLC Romania Tel: + 40 21 412 0017 office@egis.ro
Tel: + 40 21 412 0017 office@egis.ro
Eight (0.9%) patients, including 2 of those with QTcF interval prolongation of greater than 500 ms, experienced QTcF increase from baseline exceeding 60 ms.
Osam (0,9%) bolesnika, uključujući 2 bolesnika s produljenim QTcF intervalom većim od 500 ms, imalo je porast QTcF intervala u odnosu na početne vrijednosti preko 60 ms.
Eight (19%) patients had a new cytogenetic abnormality reported, including 5 patients who had changes in chromosome 7.
U osam (19%) bolesnika zabilježena je nova citogenetska abnormalnost, uključujući 5 bolesnika koji su imali promjene u kromosomu 7.
Eight (2%) tenofovir disoproxil 245 mg (as fumarate) treated patients developed the K65R mutation within the first 48 weeks.
Osam (2%) pacijenata liječenih tenofovirdizoproksilom u dozi od 245 mg (u obliku tenofovirdizoproksilfumarata) razvilo je mutaciju K65R unutar prvih 48 tjedana.
eight 25 mg tablets twice daily or two 100 mg tablets twice daily or one 200 mg tablet twice daily
osam tableta od 25 mg dva puta dnevno ili dvije tablete od 100 mg dva puta dnevno ili jedna tableta od 200 mg dva puta dnevno
Eight of these patients had DVT, one with Grade 1, two with Grade 2, four with Grade 3 and one with Grade 4.
Osam od tih bolesnika imalo je DVT, jedan stupnja 1, dva stupnja 2, četiri stupnja 3 i jedan stupnja 4.
Eight percent of patients had Grade ≥3 infusion reactions at any time during treatment.
Osam posto bolesnika imalo je reakciju na infuziju ≥ 3. stupnja u nekom trenutku tijekom liječenja.
Eight weeks after injection, around 47% of patients treated with 700 micrograms of Ozurdex achieved a vitreous haze score of zero, compared with 36% of patients treated with 350 micrograms of Ozurdex and 12% of patients who received the sham treatment.
Osam tjedana nakon injekcije oko 47 % bolesnika liječenih sa 700 mikrograma lijeka Ozurdex postiglo je rezultat zamućenosti staklovine od nula, u usporedbi s 36 % bolesnika liječenih s 350 mikrograma Ozurdexa te 12 % bolesnika koji su primali lažno liječenje.
Eight weeks later, 50.5% of the patients achieved clinical response and continued to receive maintenance dosing every 8 weeks; among these patients with continued maintenance dosing, a majority maintained response (68.1%) and achieved remission (50.2%) at week 44, at proportions that were similar to the patients who initially responded to ustekinumab induction.
Osam tjedana kasnije, 50,5% bolesnika postiglo je klinički odgovor i nastavilo je primati doziranje održavanja svakih 8 tjedana; među tim bolesnicima s kontinuiranim doziranjem održavanja, većina je zadržala odgovor (68,1%) i postiglo je remisiju (50,2%) u 44. tjednu , u udjelima koji su slični bolesnicima koji su inicijalno odgovorili na uvođenje ustekinumaba.
Eight years after vaccination, 85%, 85%, 97% and 40% were anti-HPV 6, anti-HPV 11, anti-HPV 16 and anti-HPV 18 seropositive in the cLIA, respectively, and 88%, 81%, 100% and 81% were anti-HPV 6, anti-HPV 11, anti-HPV 16 and anti-HPV 18 seropositive in the IgG LIA, respectively.
Osam godina nakon cijepljenja, 85% bilo je seropozitivno na tip 6 HPV-a, 85% na tip 11, 97% na tip 16 i 40% na tip 18, na temelju nalaza cLIA testa, a na temelju nalaza IgG LIA testa 88% bilo je seropozitivno na tip 6 HPV-a, 81% na tip 11; 100% na tip 16 i 81% na tip 18.
Eighteen cases of overdose have been reported in the literature concerning doses up to 14.4 g.
U literaturi je prijavljeno osamnaest slučajeva predoziranja koji su se odnosili na doze do 14,4 g.
Eighteen of 29 patients (62 %) with parathyroid carcinoma and 15 of 17 subjects (88 %) with primary HPT achieved a reduction in serum calcium of  1 mg/dl ( 0.25 mmol/l).
Od 29 bolesnika, 18 (62 %) s karcinomom paratireoidnih žlijezda i 15 od 17 bolesnika (88 %) s primarnim HPT-om postiglo je smanjenje serumskog kalcija od ≥ 1 mg/dl (≥ 0,25 mmol/l).
Eighteen of these 20 patients maintained virologic suppression through 48 weeks.
20 pacijenata virus je ostao suprimiran tijekom 48 tjedana.
Eighteen were evaluable for efficacy and safety and a further five patients were evaluable for toxicity only.
U osamnaest pacijenata su se mogle procijeniti djelotvornost i sigurnost, a u preostalih pet mogla se je procijeniti samo toksičnost.
Eighty percent (80%) of the subjects had a body mass index (BMI)  27.
Osamdeset posto (80%) ispitanika imalo je indeks tjelesne mase (ITM)  27.
Eighty percent of patients had received prior autologous stem cell transplantation (ASCT).
Osamdeset posto (80%) bolesnika prethodno je podvrgnuto presađivanju autolognih matičnih stanica (engl. autologous stem cell transplantation, ASCT).
Eighty-four (84) patients, 39 of whom had received two or more prior induction regimens and 31 whom had received one prior induction regimen, were treated with 650 mg/m2/day of nelarabine administered intravenously over 1 hour daily for 5 consecutive days repeated every
Osamdeset i četiri bolesnika (84), od kojih je 39 prethodno primilo 2 ili više indukcijskih terapijskih protokola, a 31 jedan indukcijski protokol, liječeno je dozom nelarabina od 650 mg/m2/dan, primijenjenom kroz 5 uzastopnih dana u obliku jednosatne intravenske infuzije.
Eighty-two percent had M1c stage, 73% had at least two and 32% of patients had three or more prior systemic therapies for advanced melanoma.
82% bolesnika imalo je stadij M1c, 73% bolesnika je prethodno primalo najmanje dvije, a njih 32% tri ili više sistemskih terapija za uznapredovali melanom.
Eimeria acervulina, strain 003 332–450
Eimeria acervulina, soj 003 332–450
Eimeria brunetti, strain 034 213–288
Eimeria brunetti, soj 034 213–288
Eimeria maxima, strain 013 196–265
Eimeria maxima, soj 013 196–265
Eimeria necatrix, strain 033 340–460
Eimeria necatrix, soj 033 340–460
Eimeria tenella, strain 004 276–374
Eimeria tenella, soj 004 276–374
Eisai AB
Eisai B.V.
Eisai Europe Limited, European Knowledge Centre, Mosquito Way, Hatfield, Herts AL10 9SN, United Kingdom
Eisai Europe Limited, European Knowledge Centre, Mosquito Way, Hatfield, Herts AL10 9SN, Ujedinjeno Kraljevstvo
Eisai Europe Limited, European Knowledge Centre, Mosquito Way, Hatfield, Herts AL10 9SN, United Kingdom
Eisai Europe Limited, European Knowledge Centre, Mosquito Way, Hatfield, Herts AL10 9SN, Velika Britanija
Eisai GesmbH
Eisai AB
Eisai Limited, European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, UK
Eisai Limited, European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, Velika Britanija
Eisai Ltd
Eisai Europe Ltd.
Eisai Ltd, European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire AL10 9SN, UK.
Eisai Ltd, European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, Velika Britanija.
Eisai Ltd, European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, UK.
Eisai Ltd, European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, Velika Britanija.
Eisai Ltd, European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, UK.
Eisai Ltd., European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, Velika Britanija
Eisai Ltd.,
Eisai Ltd.
Eisai Ltd., European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, UK.
Eisai Ltd., European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, Velika Britanija
Eisai Ltd., European Knowledge Centre, Mosquito Way, Hatfield, Herts AL10 9SN, United Kingdom
Eisai Ltd., European Knowledge Centre, Mosquito Way, Hatfield, Herts AL10 9SN, Ujedinjeno Kraljevstvo
Eisai Ltd., European Knowledge Centre, Mosquito Way, Hatfield, Herts AL10 9SN, United Kingdom.
Eisai Ltd., European Knowledge Centre, Mosquito Way, Hatfield, Herts AL10 9SN, Ujedinjeno Kraljevstvo
Eisai Ltd., European Knowledge Centre, Mosquito Way, Hatfield, Herts AL10 9SN, United Kingdom. e-mail: EUmedinfo@eisai.net
Eisai Ltd., European Knowledge Centre, Mosquito Way, Hatfield, Herts AL10 9SN, Ujedinjeno Kraljevstvo e-mail: EUmedinfo@eisai.net
Eisai Manufacturing Ltd, Mosquito Way, Hatfield, Hertfordshire AL10 9SN, UK.
Eisai Manufacturing Ltd, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, Velika Britanija
Eisai Manufacturing Ltd, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, UK
Eisai Manufacturing Ltd, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, Velika Britanija
Eisai Manufacturing Ltd, Mosquito Way, Hatfield, Herts AL10 9SN, United Kingdom.
Eisai Manufacturing Ltd, Mosquito Way, Hatfield, Herts AL10 9SN, Ujedinjeno Kraljevstvo
Eisai Manufacturing Ltd, Mosquito Way, Hatfield, Herts AL10 9SN, United Kingdom.
Eisai Manufacturing Ltd, Mosquito Way, Hatfield, Herts AL10 9SN, Velika Britanija.
Either Briviact or placebo was added to patients’ usual epilepsy treatment.
Lijekovima koji se obično upotrebljavaju u liječenju epilepsije dodan je ili Briviact ili placebo.
Either calculate the exact dose based on the individual body weight, or use the following dose volumes recommended for the different weight ranges:
Potrebno je izračunati točnu dozu na temelju individualne tjelesne mase, ili primijeniti sljedeće dozne volumene preporučene za različite raspone tjelesne mase.
either erythromycin or
na eritromicin ni na azitromicin.
either press the hinged section of the safety guard down onto a hard surface or push the hinge forward with your finger
ili pritisnite pregibni dio štitnika o tvrdu površinu ili prstom gurnite pregibni dio prema naprijed
Either ritonavir or cobicistat is used with Prezista as a ‘booster’.
Ritonavir ili cobicistat se koriste s lijekom Prezista kao
Either symptomatic disease or progressive disease alone is not enough to prompt the need of treatment with vandetanib.
Samo simptomatska bolest, ili samo progresivna bolest nisu dovoljan razlog za liječenje vandetanibom.
Either the intact PTH (iPTH) or bio- intact PTH (biPTH) may be used to measure PTH levels; treatment with cinacalcet does not alter the relationship between iPTH and biPTH.
Za određivanje vrijednosti PTH-a, treba odrediti ili intaktni PTH (iPTH) ili bio-intaktni PTH (biPTH); liječenje sinakalcetom ne mijenja odnos između iPTH-a i biPTH-a.
Either the intact PTH (iPTH) or bio-intact PTH (biPTH) may be used to measure PTH levels; treatment with Mimpara does not alter the relationship between iPTH and biPTH.
Za određivanje vrijednosti PTH-a, treba odrediti ili intaktni PTH (iPTH) ili bio-intaktni PTH (biPTH); liječenje Mimparom ne mijenja odnos između iPTH-a i biPTH-a.
either the same date (such as the 1st of each month) or the same day (such as the first Sunday of each month).
isti datum (na primjer prvi dan u mjesecu) ili isti dan (na primjer prvu nedjelju u mjesecu).
eizure
napadaje
eizure (convulsions)
napadaji (konvulzije),
eizure (convulsions),
napadaji (konvulzije),
eizure (fits)
epileptički napadaji (konvulzije)
eizure (fits) confusion
napadaje smetenost
eizure s (fits or convulsions).
napadaje (konvulzije).
eizure,
napadaji,
eizure, fainting or feeling faint, dizziness,
napadaji, nesvjestica ili osjećaj nesvjestice ili omaglica,
eizure, fainting or feeling faint, dizziness,
napadaji, nesvjestica ili osjećaj nesvjestice, omaglica,
eizure; lack of energy; inflammation of the nerves causing numbness, weakness, tingling or burning pain of the arms and legs
napadaj; manjak energije; upala živaca koja uzrokuje utrnulost, slabost, trnce ili žareću bol u rukama i nogama
eizures
napadaje
eizures
napadaji
eizures (convulsions or fits)
napadaji (konvulzije)
eizures (convulsions)
napadaje (konvulzije),
eizures (convulsions) and bipolar disorders (mood disorders characterized by alternating episodes of sadness and excitement),
napadaji (konvulzije) i bipolarni poremećaji (poremećaji raspoloženja obilježeni naizmjeničnim epizodama tuge i uzbuđenja),
eizures (convulsions),
napadaje (konvulzije),
eizures (epilepsy)
epilepsija
eizures (epilepsy)
napadaji (epilepsija)
eizures (fits)
napadaji
eizures (including febrile seizures)
napadaji (uključujući febrilne napadaje)
eizures (see section 4.4)
napadaji (vidjeti dio 4.4)
eizures,
napadaji
eizures, usually associated with a history of seizures (epilepsy)
napadaje, obično povezane s napadajima u povijesti bolesti (epilepsija)
Ejaculation
odgođena
Ejaculation
poremećaj
Ejaculation delayed (N)
odgođena ejakulacija (N)
Ejaculatory disorders, including retrograde ejaculation, anejaculation
poremećaji ejakulacije, uključujući retrogradnu ejakulaciju,
Ejection fraction decreased
manjena ejekcijska frakcija
Ejection fraction decreased
smanjena ejekcijska frakcija
Ejection fraction decreased*
manjena ejekcijska frakcija
Ejection fraction decreased, Blood bilirubin increased
smanjena ejekcijska frakcija, povišene vrijednosti bilirubina u krvi
Eklira Genuair 322 mcg inhalation powder Aclidinium (aclidinium bromide)
Eklira Genuair od 322 µg, prašak inhalata aklidinij (aklidinijev bromid)
Eklira Genuair 322 micrograms inhalation powder Aclidinium (aclidinium bromide)
Eklira Genuair 322 mikrograma, prašak inhalata aklidinij (aklidinijev bromid)
Eklira Genuair contains lactose monohydrate
Eklira Genuair sadrži laktozu hidrat
Eklira Genuair is a white or almost white powder.
Eklira Genuair je bijel ili gotovo bijeli prašak.
Eklira Genuair is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
Eklira Genuair je indiciran u terapiji održavanja bronhodilatacije za ublažavanje bronhoopstruktivnih simptoma, u odraslih bolesnika s kroničnom opstruktivnom bolesti pluća (KOPB).
Eklira Genuair is indicated for maintenance treatment of your chronic obstructive pulmonary disease, it should not be used to treat a sudden attack of breathlessness or wheezing.
Eklira Genuair se koristi u terapiji održavanja bronhodilatacije kod kronične opstruktivne bolesti pluća, i ne treba ga koristiti za liječenje iznenadnog napadaja nedostatka zraka ili piskanja.
Eklira Genuair is indicated to help open the airways and relieve symptoms of COPD, a serious, long- term lung disease characterised by breathing difficulties.
Eklira Genuair se koristi za pomoć pri otvaranju dišnih puteva i ublažavanje simptoma KOPB-a, ozbiljne, dugotrajne plućne bolesti koju karakterizira otežano disanje.
Eklira Genuair is not for use in children or adolescents below 18 years of age.
Eklira Genuair nije namijenjen djeci i adolescentima mlađim od 18 godina.
Eklira Genuair should be used with caution in patients with a myocardial infarction during the previous 6 months, unstable angina, newly diagnosed arrhythmia within the previous 3 months, or hospitalisation within the previous 12 months for heart failure functional classes III and IV as per the “New York Heart Association”.
Eklira Genuair treba koristiti oprezno kod bolesnika s infarktom miokarda u prethodnih 6 mjeseci, nestabilnom anginom, novo dijagnosticiranom aritmijom u prethodna 3 mjeseca, ili hospitalizacijom u prethodnih 12 mjeseci zbog zatajenja srca klase III i IV, prema „New York Heart Association“ (NYHA) klasifikaciji.
Eklira Genuair should not be used in asthma; clinical trials of aclidinium bromide in asthma have not been conducted.
Eklira Genuair se ne smije koristiti kod astme; nisu provedena klinička ispitivanja aklidinijeva bromida kod astme.
El Salvador 2007-2009
Salvador 2007-2009
EL-15351 Pallini Attiki Greece
EL-15351 Pallini Attiki Grčka
EL-69300 Rodopi Greece
EL-69300 Rodopi Grčka
Elanco Animal Health A/S Eli Lilly Danmark A/S Lyskær 3 E, 2. tv.
Elanco Animal Health A/S Eli Lilly Danmark A/S
Elanco Europe Ltd., Lilly House, Priestley Road, Basingstoke, RG24 9NL ,UNITED KINGDOM
Elanco Europe Ltd., Lilly House, Priestley Road, Basingstoke, RG24 9NL VELIKA BRITANIJA
Elanco France S.A. 26 Rue de la Chapelle F-68330 Huningue France
Elanco France S.A.S 26 Rue de la Chapelle F-68330 Huningue Francuska
Elanco France S.A.S 26 Rue de la Chapelle 68330 Huningue FRANCE
Elanco France S.A.S 26 Rue de la Chapelle F-68330 Huningue FRANCUSKA
Elanco France S.A.S 26 Rue de la Chapelle F-68330 Huningue FRANCE
Elanco France S.A.S 26 Rue de la Chapelle F-68330 Huningue FRANCUSKA
Elanco France S.A.S 26 Rue de la Chapelle F-68330 Huningue France
Elanco France S.A.S. 26 Rue de la Chapelle F-68330 Huningue Francuska
Elanco France S.A.S 26, Rue de la Chapelle 68330 Huningue FRANCE
Elanco France S.A.S 26, Rue de la Chapelle 68330 Huningue FRANCUSKA
Elanco France S.A.S. 26, Rue de la Chapelle 68330 Huningue France
Elanco France S.A.S. 26, Rue de la Chapelle 68330 Huningue Francuska
Elanco France S.A.S. Usine de Huningue 26 rue de Chapelle
Elanco France S.A.S. Usine de Huningue 26, rue de la Chapelle
Elaprase has been authorised under ‘exceptional circumstances’.
Lijek Elaprase odobren je u „iznimnim okolnostima”.
Elaprase is for intravenous infusion and must be diluted in sodium chloride 9 mg/ml (0.9%) solution for infusion prior to use.
Elaprase je namijenjen za intravensku infuziju i mora se prije primjene razrijediti u 0,9%-tnoj (9 mg/ml) otopini natrijevog klorida za infuziju.
elated mood (mania), confusion, lack of emotion, inability to reach orgasm
euforično raspoloženje (manija), smetenost, nedostatak emocija, nemogućnost postizanja orgazma
elated mood (mania), irritability, depression, anxiety dystonia: This is a condition involving slow or sustained involuntary contraction of muscles.
ushićeno raspoloženje (manija), razdražljivost, depresija, tjeskoba distonija: Ovo stanje uključuje spore ili kontinuirane nevoljne mišićne kontrakcije.
elbasvir (50 mg
dan)/elbasvir (50 mg
elbasvir (50 mg
elbasvir (50 mg u
elbasvir (50 mg
emtricitabinom/tenofovir
Elbasvir blocks the action of a protein called ‘NS5A’, while grazoprevir blocks an enzyme called ‘NS3/4A protease’.
„NS5A”, a grazoprevir je inhibitor enzima naziva „proteaza NS3/4A”.
Elderly
Osobe starije dobi
Elderly
Starija populacija
Elderly
Starije osobe
Elderly
Stariji bolesnici
Elderly
Stariji pacijenti
Elderly (65 years age or above)
Stariji (65 godina ili stariji)
Elderly (65 years of age and above)
Starije osobe (u dobi od 65 ili više godina)
Elderly (65 years of age and above)
Stariji bolesnici (u dobi od 65 ili više godina)
Elderly (65 years or older)
Stariji (65 godina ili više)
Elderly (75 years or older)
Starije osobe (75 godina i stariji)
Elderly (>65 years of age): Benlysta has been studied in a limited number of elderly patients.
Starije osobe (u dobi od ≥ 65 godina): Benlysta je ispitivana na ograničenom broju starijih bolesnika.
Elderly (>65 years old)
Stariji (u dobi od > 65 godina)
Elderly (>65 years)
Starije osobe (>65 godina)
Elderly (above 65 years)
Starije osobe (iznad 65 godina)
Elderly (age 65 years or over)
Starije osobe (65 godina starosti ili više)
Elderly (age 65 years or over)
Starije osobe (u dobi od 65 i više godina)
Elderly (age 75 years and over)
Starije osobe (u dobi od 75 i više godina)
Elderly (greater than or equal to 65 years of age)
Starija populacija (s navršenih 65 godina ili starija)
Elderly (over 65 years of age)
Starije osobe (iznad 65 godina)
Elderly (over 65 years of age)
Starije osobe (preko 65 godina)
Elderly (over 65 years of age)
Starije osobe (u dobi višoj od 65 godina)
Elderly (over 65 years of age) population
Starija populacija (iznad 65 godina)
Elderly (pVTEp orthopaedic surgery)
Starije osobe (pVTEp u ortopedskoj kirurgiji)
Elderly (see sections 4.2, 4.8, and 5.2).
Kod starijih osoba (vidjeti dijelove 4.2, 4.8 i 5.2).
Elderly (≥ 65 years of age)
Starije osobe (u dobi od ≥65 godina)
Elderly (≥ 65 years of age)
Starijie osobe (≥ 65 godina)
Elderly (≥ 65 years)
Stariji (≥65 godina)
Elderly (≥ 65 years)
Stariji bolesnici (≥ 65 godina)
Elderly (≥ 65 years):
Starije osobe (≥ 65 godina):
Elderly (≥65 years old)
Stariji (u dobi od > 65 godina)